Advertisement
Research Article

Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs

  • Nancy J Sullivan equal contributor,

    equal contributor Contributed equally to this work with: Nancy J Sullivan, Thomas W Geisbert

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Thomas W Geisbert equal contributor,

    equal contributor Contributed equally to this work with: Nancy J Sullivan, Thomas W Geisbert

    Affiliation: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America

    X
  • Joan B Geisbert,

    Affiliation: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America

    X
  • Devon J Shedlock,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Ling Xu,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Laurie Lamoreaux,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Jerome H. H. V Custers,

    Affiliation: Crucell Holland B.V., Leiden, Netherlands

    X
  • Paul M Popernack,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Zhi-Yong Yang,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Maria G Pau,

    Affiliation: Crucell Holland B.V., Leiden, Netherlands

    X
  • Mario Roederer,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Richard A Koup,

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Jaap Goudsmit,

    Affiliation: Crucell Holland B.V., Leiden, Netherlands

    X
  • Peter B Jahrling,

    Affiliation: Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Gary J Nabel mail

    To whom correspondence should be addressed. E-mail: gnabel@nih.gov

    Affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Published: May 16, 2006
  • DOI: 10.1371/journal.pmed.0030177

About the Authors

Nancy J Sullivan, Devon J Shedlock, Ling Xu, Laurie Lamoreaux, Paul M Popernack, Zhi-Yong Yang, Mario Roederer, Richard A Koup, Gary J Nabel
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Thomas W Geisbert, Joan B Geisbert
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America
Jerome H. H. V Custers, Maria G Pau, Jaap Goudsmit
Crucell Holland B.V., Leiden, Netherlands
Peter B Jahrling
Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

Corresponding Author

Email: gnabel@nih.gov

Competing Interests

GJN: Intellectual property on gene-based vaccines for Ebola. NJS: Intellectual property on gene-based vaccines for Ebola. ZYY: Intellectual property on gene-based vaccines for Ebola. The company Crucell is developing an Ebola vaccine.

Author Contributions

NJS, TWG, JBG, DJS, LL, and PMP contributed to animal experiments. NJS, DJS, LL, and PMP contributed to immune analyses. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to experimental design. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to data evaluation. NJS, TWG, MGP, PBJ and GJN participated in writing of the paper. LX, JHHVC, ZYY, and MGP contributed to vector construction and production.